Welcome to our dedicated page for OS Therapies SEC filings (Ticker: OSTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OS Therapies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OS Therapies's regulatory disclosures and financial reporting.
Galzahr Karim reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.
OS Therapies President and CEO Paul A. Romness reported an amended insider transaction reflecting a grant of 1,000,000 stock options on October 21, 2025. The options have an exercise price of $1.8 per share, are fully vested on the one-year anniversary of the grant date, and expire on October 21, 2035, assuming continued employment on the vesting date. Following this award, Romness beneficially owned 2,473,000 shares of common stock directly. The amendment corrects an earlier filing that had misreported the number of shares underlying this stock option grant.
OS Therapies Incorporated updated investors on its ongoing warrant inducement transaction. The company previously entered into agreements with fewer than 10 accredited investors holding existing warrants to purchase up to 5,382,148 shares of common stock. These investors were offered the opportunity to exercise, or pre-fund the exercise of, their existing warrants for cash at a reduced exercise price of $1.40 per share, or $1.399 per share in the case of pre-funding. In return, the company agreed to issue new common stock purchase warrants to purchase up to an aggregate of 5,382,148 shares at an exercise price of $1.40 per share, subject to adjustment. The company has now extended the inducement offering period from its original expiration at 11:59 p.m. Eastern time on February 10, 2026, to 11:59 p.m. Eastern time on March 2, 2026, giving holders additional time to participate.
OS Therapies Incorporated entered into warrant inducement offer letters with fewer than 10 accredited investors holding existing warrants to purchase up to 5,382,148 shares of common stock. The investors agreed to exercise these existing warrants for cash at a reduced exercise price of $1.40 per share, and in return the company will issue new warrants to purchase up to 5,382,148 additional shares at the same exercise price, exercisable immediately for five years.
The company engaged an SEC-registered broker-dealer as exclusive solicitation agent and expects aggregate gross proceeds of approximately $7.5 million, before an 8.0% cash fee to the agent and up to $25,000 of expenses. OS Therapies plans to use the net proceeds to support U.S. and international regulatory and pre-commercial efforts for OST-HER2 in osteosarcoma, to help fund spinoff preparations for its OS Animal Health subsidiary, and for general corporate purposes.
The new warrants include beneficial ownership caps of 4.99% or, at the holder’s election, 9.99%, a potential forced exercise feature if the stock trades at or above 300% of the exercise price for 20 consecutive trading days, and a cashless exercise option if a resale registration statement is not effective. The company agreed to file a resale registration statement for shares issuable upon exercise of the new warrants within 30 days of closing.
OS Therapies Inc. director reports new stock option grant and holdings. Theodore F. Search, a director of OS Therapies Inc., reported receiving stock options on 10/21/2025 to buy 140,000 shares of common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as he is still serving as a director on that date, and expire on 10/21/2035.
After this grant, he beneficially owns 140,000 stock options directly. He also reports beneficial ownership of 20,000 common shares directly and 435,835 common shares indirectly through Mill River Partners LLC, where he serves on the board of managers and shares voting and investment power.
OS Therapies Inc. filed a report showing that senior officer Robert Petit, the company’s Chief Medical Officer and Chief Scientific Officer, received a new equity award. On October 21, 2025, he was granted stock options to purchase 500,000 shares of OS Therapies common stock at an exercise price of $1.80 per share.
The options are scheduled to vest in full on the one-year anniversary of the grant date, as long as he is still employed by OS Therapies at that time. After this transaction, Petit also holds 200,000 shares of OS Therapies common stock directly, in addition to the newly granted options.
OS Therapies Inc. reported an insider equity award for its President and CEO, who is also a director. On October 21, 2025, the executive received stock options to purchase 1,950,000 shares of OS Therapies common stock at an exercise price of $1.8 per share. These options expire on October 21, 2035 and vest in full on the one-year anniversary of the grant date, as long as the executive remains employed by the company on that date.
Following this grant, the reporting person holds 2,473,000 shares of common stock directly, in addition to the newly granted 1,950,000 stock options, reflecting a significant personal equity stake in OS Therapies.
OS Therapies Inc director reports stock option grant. A director of OS Therapies Inc (OSTX) reported receiving stock options to purchase 140,000 shares of the company’s common stock on October 21, 2025, at an exercise price of $1.80 per share. The options vest in full on the one-year anniversary of the grant date, as long as the director is still serving on the board at that time, and are scheduled to expire on October 21, 2035.
OS Therapies Inc. director receives new stock option grant. A reporting person serving as a director of OS Therapies Inc. (ticker OSTX) was granted stock options on October 21, 2025 to purchase 140,000 shares of the company’s common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, as long as the individual continues to serve as a director on that date, and are scheduled to expire on October 21, 2035. Following this grant, the director beneficially owns 140,000 stock options directly.
OS Therapies Inc director reports new stock option grant and holdings. On October 21, 2025, director John Ciccio was granted stock options to buy 140,000 shares of OS Therapies Inc common stock at an exercise price of $1.8 per share. These options vest in full on the one-year anniversary of the grant date, if he is still serving as a director on that date, and expire on October 21, 2035.
After the reported transactions, he beneficially owns 435,835 shares of common stock indirectly through Mill River Partners LLC and 20,000 shares directly, in addition to the 140,000 stock options held directly.